Sign In
Buy ALEC
$1.78
-0.175 (-8.97%)
At Close: Jun 03, 2026
Why Clovis Oncology, Marker Therapeutics, Alector Are Rallying Friday
12:43pm, Friday, 19'th Mar 2021
Clovis Oncology, Inc. (NASDAQ: CLVS), Marker Therapeutics, Inc. (NASDAQ: MRKR) and Alector, Inc. (NASDAQ: ALEC) are among the biggest biotech gainers Friday. Clovis Jumps On Ovarian Cancer Data: Clovi
Alector to Present at the Barclays Global Healthcare Conference
04:05pm, Thursday, 04'th Mar 2021
SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman
Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer's Disease
08:30am, Monday, 25'th Jan 2021
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the first particip
Alector Announces Departure of Chief Business Officer
04:15pm, Wednesday, 20'th Jan 2021
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that chief business off
Alector Provides 2021 Corporate Portfolio Update
04:05pm, Thursday, 07'th Jan 2021
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today provided a preview of its planne
Alector: Activating Microglia To Treat Neurodegeneration
10:39am, Monday, 28'th Dec 2020
Alector is a leader in neuroimmunology drug development. This has enabled the company to build a pipeline of medicines pursuing large and important markets from dementia and Alzheimer's.
Alector: AL001's Phase 3 Initiation/Phase 2 Readout In 2021, $462M In Cash, And AbbVie's Promising Support, +38% Upside
04:47pm, Monday, 07'th Dec 2020
Alector, Inc (Nasdaq: ALEC) is a clinical-stage biopharmaceutical company focused on immuno-neurology, immune dysfunction studies related to degenerative brain disorders. Alector has 4-clinical phase
Alector to Present at the Stifel 2020 Virtual Healthcare Conference
04:05pm, Wednesday, 11'th Nov 2020
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney, Ph.D.
Alector (ALEC) Reports Q3 Loss, Misses Revenue Estimates
06:45pm, Tuesday, 10'th Nov 2020
Alector (ALEC) delivered earnings and revenue surprises of -24.07% and -22.62%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Alector Reports Third Quarter 2020 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 10'th Nov 2020
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced corporate updates and
Alector Provides Update on Arbitration Proceedings with Dr. Asa Abeliovich
07:44am, Monday, 02'nd Nov 2020
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that an independent arb
Alector (ALEC) Investor Presentation - Slideshow
01:53pm, Monday, 14'th Sep 2020
The following slide deck was published by Alector, Inc. in conjunction with this event..
Wall Street Breakfast: The Week Ahead
06:41am, Sunday, 13'th Sep 2020
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
Stocks To Watch: Apple, Snowflake, Pfizer And Moderna In Focus
08:40am, Saturday, 12'th Sep 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs
12:00am, Wednesday, 19'th Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 18)
Avenue Therapeutics Inc (NASDAQ: ATXI)
Checkmate Pharmaceuticals Inc (NASDAQ: CMPI)
DarioHealth Corp (NASDAQ:...
